Protagonist Therapeutics PTGX
Valuation
Multiples measured against the stock's own five-year history
Above its usual level · 78th percentile, 5-year average 16.6x
#2056 of 2994 stocks by PE (1 = cheapest)
Near the top of its 5-year range · 80th percentile, 5-year average 5.3x
#4797 of 5331 stocks by PB (1 = cheapest)
Below its usual level · 35th percentile, 5-year average 260.1x
#4656 of 5155 stocks by PS (1 = cheapest)
P/E over five years
Dashed line is the 5-year average; the shaded band is one standard deviation either side.
Morningstar fair value estimate
| Multiple | Current | Forward | 5y average | Percentile vs. own history | Industry rank |
|---|---|---|---|---|---|
| PB | 7.88 | – | 5.29 | 80% (pricier than usual) | #4797 of 5331 (1 = cheapest) |
| PE | 27.68 | 45.94 | 16.61 | 78% (pricier than usual) | #2056 of 2994 (1 = cheapest) |
| PS | 15.49 | 34.40 | 260.14 | 35% (cheaper than usual) | #4656 of 5155 (1 = cheapest) |
Percentile is against this stock’s own 5-year valuation range: higher means it’s trading rich relative to its own history, lower means cheap relative to its own history — it is not a comparison against other companies. Forward multiples use consensus estimates for the next twelve months; a forward multiple below the current one usually signals analysts expect earnings to grow.
No comments yet — be the first to weigh in on PTGX.
Sign in to join the discussion.